Memantin Abdi (Memantine Hydrochloride)

Memantine works as a non‑competitive antagonist of the NMDA receptor. By blocking excessive calcium influx caused by prolonged glutamate activation, it reduces excitotoxic neuronal injury while preserving normal synaptic transmission, which supports neuronal health in Alzheimer’s disease.

The appropriate dose of memantine is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Dosage titration typically starts at a low level and may be increased gradually, but exact regimens should follow the prescriber’s instructions.

Safety of memantine during pregnancy and lactation has not been established. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Memantin Abdi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas the most common alternative for Alzheimer’s disease is the acetylcholinesterase inhibitor class (e.g., donepezil). Memantine targets glutamate‑mediated excitotoxicity, while acetylcholinesterase inhibitors enhance cholinergic transmission. Clinical choice depends on disease stage, patient tolerance and physician judgment.

Memantin Abdi should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight, and excessive heat. Keep out of reach of children and do not use if the packaging is damaged.

Memantin Abdi is administered orally. The tablet should be swallowed whole with a glass of water, preferably with food to reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider and should not crush or chew the tablet.

Serious risks associated with memantine include the possibility of seizures, severe allergic reactions such as anaphylaxis, and neuropsychiatric events like hallucinations or psychosis. Patients should seek immediate medical attention if they experience any of these symptoms.

Memantine should not be used by individuals with known hypersensitivity to memantine or any of its excipients. Caution is advised in patients with severe renal impairment, uncontrolled cardiovascular disease, or a history of seizures, as these conditions may increase the risk of adverse effects.